Medpace Holdings, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Medpace Holdings, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $294.76M, a 45.51% decline year-over-year.
- Medpace Holdings, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Medpace Holdings, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Medpace Holdings, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $4.57M.
- Medpace Holdings, Inc. payments for repurchase of common stock for fiscal 2025 was $917.39M, a 440.06% increase from fiscal 2024.
- Medpace Holdings, Inc. payments for repurchase of common stock for fiscal 2024 was $169.87M, a 17.95% increase from fiscal 2023.
- Medpace Holdings, Inc. payments for repurchase of common stock for fiscal 2023 was $144.02M, a 83.01% decline from fiscal 2022.
- Medpace Holdings, Inc. payments for repurchase of common stock for fiscal 2022 was $847.85M, a 1265.38% increase from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $294.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $299.34M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-23 | $545.49M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $917.39M 10-K · filed 2026-02-10 |
| 2025-09-30 | $4.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $1.09B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $540.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $1.08B derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $371.90M 10-Q · filed 2026-04-23 | $541.77M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $169.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $169.87M 10-K · filed 2026-02-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $0.00 derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $0.00 10-Q · filed 2025-04-22 | $23.87M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $144.02M 10-K · filed 2026-02-10 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $191.20M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $23.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $191.20M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $120.15M 10-Q · filed 2024-04-23 | $542.04M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $47.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $847.85M 10-K · filed 2025-02-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | $800.67M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $374.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $806.89M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $425.95M 10-Q · filed 2023-04-25 | $488.05M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $62.10M 10-K · filed 2024-02-13 |
| 2021-09-30 | $6.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $109.54M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $55.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-26 | $103.32M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-27 | $56.50M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $47.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $98.27M 10-K · filed 2023-02-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-26 | $50.83M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $9.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $50.83M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $41.78M 10-Q · filed 2021-04-27 | $41.78M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $0.00 derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | $0.00 derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-29 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $0.00 10-K · filed 2021-02-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | |
| 2017-12-31 | $60.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $155.58M 10-K · filed 2020-02-25 |
| 2017-09-30 | $68.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | |
| 2017-06-30 | $26.40M 10-Q · filed 2017-08-01 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $0.00 10-K · filed 2019-02-26 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | |
| 2015-12-31 | $0.00 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |